TMDX (TransMedics Group) stock outlook for 2026. A qualitative deep dive into how the OCS perfusion device replaces the ice cooler, the equipment-plus-consumables-plus-aviation model, the organ utilization thesis, and the valuation, execution, regulatory, and short-seller risks.
Análisis de Hologic (NASDAQ: HOLX) para 2026: la base instalada de sistemas moleculares Panther y el pull-through de ensayos, la mamografía 3D Genius y sus ingresos recurrentes de servicio, la normalización tras el pico de tests COVID hacia una base orgánica limpia, el foso de salud femenina, las recompras y el M&A tuck-in, más los riesgos competitivos de Roche, BD, GE HealthCare y Siemens.
Hologic (NASDAQ: HOLX) stock analysis for 2026: the Panther molecular installed base and assay pull-through, 3D Genius mammography and recurring service revenue, the post-COVID normalization to a clean organic-growth base, the women's-health moat, tuck-in M&A and buybacks, plus competitive risk from Roche, BD, GE HealthCare and Siemens.
UHS (Universal Health Services) 2026 stock outlook. A deep qualitative look at its two engines — acute-care hospitals and a very large behavioral-health franchise — plus the secular mental-health tailwind, labor and reimbursement pressure, regulatory and litigation risk, and the Miller family's long buyback record.
GE HealthCare GEHC stock outlook 2026: post-GE spinoff re-rating, MRI/CT/ultrasound global positioning, contrast media moat, Siemens Healthineers vs Philips competitive analysis, and US investor tax strategy for Roth IRA and taxable accounts.
Illumina ILMN stock outlook 2026: post-GRAIL divestiture focus, NovaSeq X consumables cycle, razor-razorblade moat, MGI-Element-Ultima competitive threats, and a framework for US investors in taxable accounts, Roth IRA, and 401(k).